Effect of urate LowEring Agent Febuxostat in Chronic Heart Failure patients with hyperuricemia - LEAF-CHF study

EAF-CHF steering committee0 个研究点目标入组 200 人开始时间: 2014年3月4日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1) Drugs for hyperuricemia, within 2 weeks before confirmation of eligibility. Allopurinol, Benzbromarone, Probenecid, Bucolome, Topiroxostat, Febuxostat (2) Drugs at the time of confirmation of eligibility. Mercaptopurinehydrate, Azathioprine, Vidarabine, Dinanosine (3) Gouty tophus or certain symptom of gouty arthritis within 1 year before eligibility confirmation. (4) Acute myocardial infarction or coronary arterial revascularization within 3 month before eligibility confirmation. (5) Planned cardiac surgery such as coronary arterial valve operation, during participation of this study. (6) Heart failure caused by valvular heart disease or congenital heart disease. (7) Severe hepatic, or renal dysfunction, dialysis or malignancy disqualified from the study by the investigators. Severe hepatic dysfunction is defined as twice the upper limit of baseline AST or ALT. Severe renal dysfunction is defined as eGFR <30/mL/min/1.73m2. eGFR is calculated by formula shown in "CKD diagnostic guideline 2012 by Japanese Society of Nephropathy" eGFR(mL/min/1.73m2)=194*Cr^(-1.094)*Age^(-0.287)(Female *0.739) (8) Febuxostat hypersensitivity. (9) Pregnant, possibly pregnant, brest-feeding, or expecting to conceive. (10)Participated in other clinical study within 6 months before confirmation of eligibility. (11)Considered to be inappropriate for the participation in this study by the investigators.

发起方

EAF-CHF steering committee